Why BI Bid Farewell To Biosimilars
The German group pharma's chief told Scrip "innovation drives the business" and confirmed that biosimilars have been abandoned apart from its Humira version Cyltezo in the US.
You may also be interested in...
Boehringer Ingelheim has won a landmark first US interchangeability designation for a biosimilar to Humira, with the firm’s Cyltezo version of adalimumab representing the second ever interchangeable biosimilar approved by the FDA.
Boehringer Ingelheim has settled litigation with AbbVie over Humira by striking a deal that allows it to launch its biosimilar adalimumab in the US from the start of July 2023.
The German major believes its drug will remain the biggest-selling SGLT-2 inhibitor boosted by expanded heart and renal disease approvals.